Mesoblast limited (NASDAQ:MESO)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $4.47 and last traded at $4.66, with a volume of 42221 shares. The stock had previously closed at $4.76.
MESO has been the topic of several recent analyst reports. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Thursday, August 30th. HC Wainwright set a $17.00 target price on shares of Mesoblast and gave the stock a “buy” rating in a research report on Thursday, August 30th. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Wednesday, September 19th. ValuEngine raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Wednesday, September 26th. Finally, TheStreet raised shares of Mesoblast from a “d+” rating to a “c-” rating in a research report on Monday, October 1st. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $13.96.
The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $457.67 million, a P/E ratio of -7.40 and a beta of 1.89.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/05/mesoblast-meso-hits-new-12-month-low-at-4-47.html.
About Mesoblast (NASDAQ:MESO)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.